Lessons Learned: New FDA Guidance On Meetings With Sponsors Adds Depth
Executive Summary
FDA's new iteration of its guidance on meetings with sponsors reflects lessons learned during the surge in meeting requests the agency has had in the nine years since the original formal meetings final guidance was issued in February 2000
You may also be interested in...
REMS, ‘Breakthrough’ Meetings Get ‘Type B’ Tag In Revised FDA Guidance
In other modifications, FDA tells sponsors seeking Type A meetings – the most urgent category – that data packages must accompany the request.
BIO Chairman Sees "Science-Driven" Hamburg As Plus For Regulatory Climate
BIO Board Chairman Stephen Sherwin is looking forward to an improved regulatory environment at FDA for biopharmaceutical companies with the advent of Margaret Hamburg as agency commissioner
BIO Chairman Sees "Science-Driven" Hamburg As Plus For Regulatory Climate
BIO Board Chairman Stephen Sherwin is looking forward to an improved regulatory environment at FDA for biopharmaceutical companies with the advent of Margaret Hamburg as agency commissioner